Related Experiment Video
Updated: Mar 8, 2026
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Targeting canine mammary tumours via gold nanoparticles functionalized with promising Co(II) and Zn(II) compounds
L R Raposo1,2, C Roma-Rodrigues1, J Jesus1
1UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Caparica, Portugal.
Background:
Despite continuous efforts, the treatment of canine cancer has still to deliver effective strategies. For example, traditional chemotherapy with doxorubicin and/or docetaxel does not significantly increase survival in dogs with canine mammary tumors (CMTs).
Aims:
Evaluate the efficiency of two metal compounds [Zn(DION)2 ]Cl (TS262, DION = 1,10-phenanthroline-5,6-dione) and [CoCl(H2 O)(DION)2 ][BF4 ] (TS265) and novel nanovectorizations designed to improve the anti-cancer efficacy of these compounds in a new CMT derived cell line (FR37-CMT).
Materials And Methods:
FR37-CMT cells were exposed to different concentrations of TS262 and TS265 and two new nanoparticle systems and cellular viability was determined. These nanosystems are composed of polyethylene-glycol, bovine-serum-albumin and TS262 or TS265 (NanoTS262 or NanoTS265, respectively).
Results:
In FR37-CMT, TS262 and TS265 displayed IC50 values well below those displayed by doxorubicin and cisplatin. The nanovectorizations further decreased the IC50 values.
Discussion:
TS262 and TS265 proved to be effective against FR37-CMT cells and more effective than of doxorubicin and cisplatin. The Nanosystems efficiently delivered the cytotoxic cargo inducing a significant reduction of cell viability in FR37-CMT cell line when compared to the free compounds.
Conclusions:
TS262 and TS265 are compounds with potential in the treatment of CMTs. NanoTS262 and NanoTS265 demonstrate that such simple nanovectorization via gold nanoparticles shows tremendous potential as anti-cancer formulations, which may easily be expanded to suit other cargo.
Insights
New metal compounds, TS262 and TS265, show significant potential for treating canine mammary tumors (CMTs). Nanoparticle formulations of these compounds further enhance their anti-cancer efficacy, offering a promising new strategy for canine cancer therapy.
Area of Science:
- Veterinary Oncology
- Nanomedicine
- Metal-based Chemotherapeutics
Background:
- Current treatments for canine cancer, including chemotherapy with doxorubicin and docetaxel, offer limited survival benefits for canine mammary tumors (CMTs).
- There is a critical need for more effective therapeutic strategies to combat canine mammary tumors.
Purpose of the Study:
- To evaluate the anti-cancer efficacy of two novel metal compounds, [Zn(DION)2 ]Cl (TS262) and [CoCl(H2 O)(DION)2 ][BF4 ] (TS265), against a CMT-derived cell line (FR37-CMT).
- To assess the improved anti-cancer activity of TS262 and TS265 when delivered via novel nanovectorization systems.
Main Methods:
- FR37-CMT cells were treated with varying concentrations of TS262 and TS265, as well as their nanoparticle formulations (NanoTS262 and NanoTS265).
- Cellular viability was determined using IC50 values to quantify the cytotoxic effects of the compounds and nanosystems.
- Nanosystems were composed of polyethylene-glycol, bovine-serum-albumin, and either TS262 or TS265.
Main Results:
- TS262 and TS265 demonstrated significantly lower IC50 values compared to doxorubicin and cisplatin in FR37-CMT cells.
- The nanovectorized formulations (NanoTS262 and NanoTS265) further reduced the IC50 values, indicating enhanced cytotoxicity.
- Nanosystems effectively delivered the cytotoxic agents, leading to a substantial decrease in FR37-CMT cell viability compared to free compounds.
Conclusions:
- TS262 and TS265 exhibit potent anti-cancer activity against FR37-CMT cells, outperforming established chemotherapeutics like doxorubicin and cisplatin.
- Simple nanovectorization using nanoparticles significantly enhances the delivery and efficacy of TS262 and TS265 against canine mammary tumors.
- These findings highlight the potential of NanoTS262 and NanoTS265 as promising anti-cancer formulations for CMTs, with potential for broader applications.
More Related Videos
09:23Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods
Published on: October 10, 2025
10:51Protocols for Assessing Radiofrequency Interactions with Gold Nanoparticles and Biological Systems for Non-invasive Hyperthermia Cancer Therapy
Published on: August 28, 2013